CD274 and cancer: The introduction of immunotherapy into clinical practice represents a significant development in cancer treatment, with the PD-1/PD-L1 (programmed death ligand 1; CD274; gene CD274) pathway being a primary target of this strategy in several cancers, including NSCLC.